Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript

Galapagos NV (GLPG) Q4 2025 Earnings Call Transcript

Seeking Alpha • 7 hours ago

Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Mechelen, Belgium; February 23, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the full year 2025 and provided an update on the fourth quarter 2025 and its year-to-date performance.

GlobeNewsWire • Feb 23, 2026

Galapagos Receives Transparency Notification from Bank of America

Mechelen, Belgium ; February 16, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Bank of America.

GlobeNewsWire • Feb 16, 2026

Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities

Mechelen, Belgium ; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its Board of Directors has decided to initiate the wind-down of the Company's cell therapy activities.

GlobeNewsWire • Jan 5, 2026

Galapagos: Pivoting From Clinical Risk To Strategic Capital Allocation

Galapagos now presents a deep value opportunity, underpinned by a €3B cash reserve and a decisive shift to capital allocation discipline. GLPG's restructuring—discontinuing cell therapy, slashing headcount, and targeting cash flow neutrality by YE2026—positions it as a streamlined M&A platform. Management's M&A-focused pedigree, led by ex-AbbVie dealmakers, signals a pivot from pipeline reliance to transformative business development using its cash war chest.

Seeking Alpha • Dec 22, 2025

Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025

High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time

GlobeNewsWire • Dec 8, 2025

Galapagos Receives Transparency Notifications from Bank of America

Mechelen, Belgium ; November 26, 2025, 07:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America.

GlobeNewsWire • Nov 26, 2025

Galapagos NV (GLPG) Q3 2025 Earnings Call Transcript

Galapagos NV ( GLPG ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Glenn Schulman Henry Gosebruch - CEO & Executive Director Aaron Cox - Chief Financial Officer Dan Grossman - Chief Strategy Officer Conference Call Participants Faisal Khurshid - Leerink Partners LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Philip Nadeau - TD Cowen, Research Division Chi Meng Fong - BofA Securities, Research Division Jacob Mekhael - KBC Securities NV, Research Division Sebastiaan van der Schoot Delphine Le Louet - Sanford C. Bernstein & Co., LLC.

Seeking Alpha • Nov 6, 2025

Galapagos to Present New Data from Cell Therapy Program at ASH 2025

Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma

GlobeNewsWire • Nov 3, 2025

Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors

Mechelen, Belgium ; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG3667, currently in two Phase 3-enabling studies in dermatomyositis (DM) and systemic lupus erythematosus (SLE), at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago, IL, October 24-29, 2025.

GlobeNewsWire • Oct 23, 2025